Clinical Trial Update: Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease [Phase 1, Phase 2]

View source ↗

Summary

Open-label study of AVR-RD-01 for treatment-naive Fabry disease subjects in Phase 1/2 was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• AVR-RD-01

Snippet

Sponsor: AVROBIO | Conditions: Fabry Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-01-05